Over 20 Total Lots Up For Auction at One Location - TX Cleansweep 06/25

Proton therapy current events recap

por Gus Iversen, Editor in Chief | March 29, 2021
Rad Oncology Proton Therapy
From the March 2021 issue of HealthCare Business News magazine

C-RAD Sentinel 4DCT is an easy-to-use, laser-based optical surface scanning system with functionality for four-dimensional CT image reconstruction and gated imaging in a CT room.

The total order has a value of 15 MSEK for C-RAD. Delivery and installation for the first center are expected to be concluded during the next three months. The other sites will follow in 2021 and 2022.

ProTom International inks China distribution deal
ProTom International Holding Corporation announce in January that it signed a distribution and licensing agreement in China. The arrangement was made with Guohong Guokang (Beijing) Health Technology Development Co., LTD ("GHGK") for exclusive rights to distribute ProTom's Radiance 330 Proton Therapy System in mainland China.

Under the agreement, ProTom also provides for the exclusive distribution rights to expand to certain other countries over time, and establishes a co-marketing area where ProTom and GHGK will work together to distribute the Radiance 330 in other Asia-Pacific countries.

“As the world's largest market, China brings unique challenges in bringing new cancer therapy to improve the lives of cancer patients and their families,” said Stephen Spotts, CEO of ProTom in a statement. “The relationship we have established with GHGK overcomes these challenges and brings together the strengths of the two companies with the common goal of broader access to this life changing cancer treatment.”

GHGK is a proton therapy technology platform company established by the Sino Hope Group especially for the distribution of ProTom's Radiance 330 system.

Varian installs world's first ProBeam 360 at Penn Medicine
In February, Varian announced it had started the installation of the cyclotron and gantry for its ProBeam 360 single-room proton therapy system at Penn Medicine Lancaster General Health's Ann B. Barshinger Cancer Institute.

The Ann B. Barshinger Cancer Institute, which is part of Penn Medicine Lancaster General Health, has become the first treatment center in the world to have a ProBeam 360 system from Varian. The center is expected to treat its first patients in 2022.

"Varian is proud of our longstanding collaboration with Penn Medicine, which goes back decades and encompasses joint innovation, clinical research, training and education, and bringing new technologies to cancer patients," said Kolleen Kennedy, chief growth officer and president of proton therapy solutions at Varian, in a statement. "We're especially pleased to be taking this next step with them, delivering the latest innovations in proton therapy technology for the cancer patients of South Central Pennsylvania."

The cyclotron is a particle accelerator that accelerates protons to extremely fast speeds; roughly 100,000 miles per second or roughly two-thirds the speed of light, to create a beam that can precisely reach tumors wherever they are in the body.

Back to HCB News

You Must Be Logged In To Post A Comment